Triple

T4061239
Position Surface form Disambiguated ID Type / Status
Subject Center for Biologics Evaluation and Research E86214 entity
Predicate hasDivision P35 FINISHED
Object Office of Compliance and Biologics Quality
The Office of Compliance and Biologics Quality is a division within the FDA’s biologics center responsible for ensuring the safety, quality, and regulatory compliance of biological products such as vaccines, blood, and cellular therapies.
E409912 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Office of Compliance and Biologics Quality | Statement: [Center for Biologics Evaluation and Research, hasDivision, Office of Compliance and Biologics Quality]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Office of Compliance and Biologics Quality
Context triple: [Center for Biologics Evaluation and Research, hasDivision, Office of Compliance and Biologics Quality]
  • A. Center for Biologics Evaluation and Research
    The Center for Biologics Evaluation and Research is the U.S. regulatory body responsible for overseeing the safety, efficacy, and quality of biological products such as vaccines, blood products, and gene therapies.
  • B. Office of Pharmaceutical Quality
    The Office of Pharmaceutical Quality is a U.S. Food and Drug Administration office responsible for ensuring the quality, safety, and consistency of human drugs throughout their lifecycle.
  • C. Office of Regulatory Affairs
    The Office of Regulatory Affairs is the U.S. FDA’s primary field organization responsible for inspecting regulated products and manufacturers, enforcing compliance, and overseeing import operations to protect public health.
  • D. Center for Drug Evaluation and Research
    The Center for Drug Evaluation and Research is the U.S. FDA division responsible for overseeing the safety, effectiveness, and quality of prescription and over-the-counter drugs.
  • E. Office of Quality and Compliance
    The Office of Quality and Compliance is a division within the Oregon Department of Human Services responsible for overseeing adherence to standards, regulations, and best practices to ensure effective and accountable delivery of human services.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Office of Compliance and Biologics Quality
Triple: [Center for Biologics Evaluation and Research, hasDivision, Office of Compliance and Biologics Quality]
Generated description
The Office of Compliance and Biologics Quality is a division within the FDA’s biologics center responsible for ensuring the safety, quality, and regulatory compliance of biological products such as vaccines, blood, and cellular therapies.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: Office of Compliance and Biologics Quality
Target entity description: The Office of Compliance and Biologics Quality is a division within the FDA’s biologics center responsible for ensuring the safety, quality, and regulatory compliance of biological products such as vaccines, blood, and cellular therapies.
  • A. Center for Biologics Evaluation and Research
    The Center for Biologics Evaluation and Research is the U.S. regulatory body responsible for overseeing the safety, efficacy, and quality of biological products such as vaccines, blood products, and gene therapies.
  • B. Office of Pharmaceutical Quality
    The Office of Pharmaceutical Quality is a U.S. Food and Drug Administration office responsible for ensuring the quality, safety, and consistency of human drugs throughout their lifecycle.
  • C. Office of Regulatory Affairs
    The Office of Regulatory Affairs is the U.S. FDA’s primary field organization responsible for inspecting regulated products and manufacturers, enforcing compliance, and overseeing import operations to protect public health.
  • D. Center for Drug Evaluation and Research
    The Center for Drug Evaluation and Research is the U.S. FDA division responsible for overseeing the safety, effectiveness, and quality of prescription and over-the-counter drugs.
  • E. Office of Quality and Compliance
    The Office of Quality and Compliance is a division within the Oregon Department of Human Services responsible for overseeing adherence to standards, regulations, and best practices to ensure effective and accountable delivery of human services.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69aed93c69208190a4efac0efe3cd69b completed March 9, 2026, 2:29 p.m.
NER Named-entity recognition batch_69aefbd4acb0819093bcffcd05ed8e6f completed March 9, 2026, 4:56 p.m.
NED1 Entity disambiguation (via context triple) batch_69b562ac25848190951431c9c853cc59 completed March 14, 2026, 1:29 p.m.
NEDg Description generation batch_69b5633103e081909dbe7a7e54877343 completed March 14, 2026, 1:31 p.m.
NED2 Entity disambiguation (via description) batch_69b563eca17c81908deff0d361a7be87 completed March 14, 2026, 1:34 p.m.
Created at: March 9, 2026, 3:38 p.m.